glp-1 agonist or antagonist Mechanisms of Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation Biased agonism and polymorphic variation

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license)

B.WangB.GardnerE

47 SGLT2-I approved in the US for the treatment of T2DM include canagliflozin (Invokana, 2013), dapagliflozin (Farxiga, 2014), and empagliflozin (Jardiance, 2014)

(NIDDK) Blood sugar becomes more stable, which can reduce the drive to eat in response to large metabolic swings

Form Health may recommend GLP-1 treatment for adults with a BMI of 30 or above, or a BMI of 27 when accompanied by a weight-related condition

Both classes are resistant to the enzymatic degradation seen for native GLP-1, which is cleaved by the DPP-IV enzyme to generate inactive metabolites and intact GLP-1 forms with low affinity for the GLP-1R